Table I.

FDA-approved Targeted Drugs in Triple-Negative Breast Cancer

Drug	Indication	Pivotal Trial
Atezolizumab	In combination with nab-paclitaxel for unresectable locally advanced or metastatic TNBC whose tumors are PD-L1-positive (PD-L1 stained tumor infiltrating immune cells ≥1%)	Impassion130 (NCT02425891)
Olaparib	Deleterious or suspected deleterious gBRCAm, HER-2 negative metastatic breast cancer previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting	OlympiAD (NCT02000622)
Talazoparib	Deleterious or suspected deleterious gBRCAm, HER-2 negative locally advanced or metastatic breast cancer	EMBRCA (NCT01945775)
Sacituzumab govitecan-hziy	Metastatic TNBC who received at least two prior lines of therapy for metastatic disease	IMMU-132-01 (NCT01631552)

Abbreviations: gBRCAm: germline BRCA-mutated